Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News
Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRoche unveils data behind BTK inhibitor’s phase 3…
SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…
Big Pharma Forces Britain to Take Its Medicine
Global drugmakers including Merck & Co., Eli Lilly & Co. and AstraZeneca Plc are pausing or canceling investments…